tert-butyl 4-(5-bromopyridin-2-yl)-4-cyanopiperidine-1-carboxylate | 1196973-42-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: tert-butyl 4-(5-bromopyridin-2-yl)-4-cyanopiperidine-1-carboxylate
• 英文别名: 4-(5-Bromopyridin-2-yl)-4-cyanopiperidine-1-carboxylic acid tert-butyl ester
• CAS: 1196973-42-8
• 化学式: C₁₆H₂₀BrN₃O₂
• 分子量: 366.258
• InChiKey: UUSVVGCOFAICLB-UHFFFAOYSA-N

物化性质

• 沸点：
  469.4±45.0 °C(Predicted)
• 密度：
  1.40±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  66.2
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-(5-bromopyridin-2-yl)-4-cyanopiperidine-1-carboxylate 在 盐酸 作用下， 以 水 为溶剂， 以76 %的产率得到5-bromo-2-(piperidin-4-yl)pyridine dihydrochloride
  参考文献：
  名称：

  通过（杂）脂肪族腈的 α-芳基化多克合成 α-和 γ-（（杂）环）烷基吡啶

  摘要：

  (环)烷基吡啶：描述了用 2- 和 4- 氟吡啶衍生物对腈和酯阴离子进行S N Ar 芳基化的系统研究。结合水解和脱羧，该方法为多克合成在 α 或 γ 位上用烷基、环烷基和饱和杂环取代基修饰的官能化吡啶提供了一种有效的方法，这些取代基是药物化学的重要组成部分。

  DOI：

  10.1002/ejoc.202300538
• 作为产物：
  描述：

  2,5-二溴吡啶 、 N-Boc-4-氰基哌啶 在 lithium hexamethyldisilazane 作用下， 以 甲苯 为溶剂， 反应 16.0h， 以100%的产率得到tert-butyl 4-(5-bromopyridin-2-yl)-4-cyanopiperidine-1-carboxylate
  参考文献：
  名称：

  Preparation of 4-heteroaryl-4-cyanopiperidines via SNAr substitution reactions

  摘要：

  The scope and limitations of SNAr substitution reactions of metalated 4-cyanopiperidines with heterocyclic halides were explored. These facile reactions provide rapid access to a wide range of 4-heteroaryl-4-cyanopiperidines and have resulted in improved yields, faster reaction times, and lower temperatures than previously published synthetic methods. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2009.08.123

文献信息

• BICYCLIC HETEROCYCLES AS FGFR INHIBITORS
  申请人：Incyte Corporation

  公开号：US20210106588A1

  公开（公告）日：2021-04-15

  The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR enzyme and are useful in the treatment of FGFR-associated diseases such as cancer.

  这项发明涉及双环杂环化合物及其药物组合物，这些化合物是FGFR酶的抑制剂，可用于治疗与FGFR相关的疾病，如癌症。
• AMIDE DERIVATIVE AND USE THEREOF
  申请人：Ushio Hiroyuki

  公开号：US20130211075A1

  公开（公告）日：2013-08-15

  The present invention relates to a novel amide derivative. More specifically, the present invention provides a medicinal agent useful as a prophylactic or therapeutic agent for diseases, which relies on the production of cytokines from T cells, and which comprises an amide derivative or a pharmacologically acceptable salt thereof or a solvate of the derivative or the pharmacologically acceptable salt as an active ingredient. Provided is an amide derivative represented by general formula (I) [wherein each symbol is as defined in the description] or a pharmacologically acceptable salt thereof, or a solvate of the derivative or the pharmacologically acceptable salt.

  本发明涉及一种新型酰胺衍生物。更具体地说，本发明提供了一种药用剂，可用作依赖于T细胞产生细胞因子的疾病的预防或治疗剂，该药用剂包括酰胺衍生物或其药理学上可接受的盐或该衍生物或药理学上可接受的盐的溶剂的溶剂作为活性成分。提供的是由通式(I)所表示的酰胺衍生物[其中每个符号如描述中所定义]或其药理学上可接受的盐，或该衍生物或药理学上可接受的盐的溶剂。
• Amide derivative and use thereof
  申请人：Ushio Hiroyuki

  公开号：US09150555B2

  公开（公告）日：2015-10-06

  The present invention relates to a novel amide derivative. More specifically, the present invention provides a medicinal agent useful as a prophylactic or therapeutic agent for diseases, which relies on the production of cytokines from T cells, and which comprises an amide derivative or a pharmacologically acceptable salt thereof or a solvate of the derivative or the pharmacologically acceptable salt as an active ingredient. Provided is an amide derivative represented by general formula (I) [wherein each symbol is as defined in the description] or a pharmacologically acceptable salt thereof, or a solvate of the derivative or the pharmacologically acceptable salt.

  本发明涉及一种新型酰胺衍生物。更具体地说，本发明提供了一种药物剂，其可作为预防或治疗疾病的药物剂，依赖于T细胞产生细胞因子，并包括酰胺衍生物或其药理学上可接受的盐或衍生物或药理学上可接受的盐的溶剂作为活性成分。提供了一种由通式（I）表示的酰胺衍生物[其中每个符号如定义中所述]或其药理学上可接受的盐，或其衍生物或药理学上可接受的盐的溶剂。
• US9150555B2
  申请人：——

  公开号：US9150555B2

  公开（公告）日：2015-10-06
• [EN] BICYCLIC HETEROCYCLES AS FGFR INHIBITORS<br/>[FR] HÉTÉROCYCLES BICYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS DE FGFR
  申请人：INCYTE CORP

  公开号：WO2021076602A1

  公开（公告）日：2021-04-22

  The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR enzyme and are useful in the treatment of FGFR-associated diseases such as cancer. Formula (I).